ArticleMolecular biology reports2025
JI017 induces cell line specific anticancer effects in hepatocellular carcinoma by suppressing the STAT3 signaling pathway.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic and chemopreventive potential of melatonin in liver diseases: targeting oxidative stress and inflammatory signaling.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC), a predominant cause of cancer-related mortality, is commonly linked to constitutive activation of oncogenic pathways such as STAT3. Continuous STAT3 activation drives tumor progression by enhancing proliferation, survival, and metastatic capability, thus presenting a rational therapeutic target. JI017, an herbal product-based formulation containing Angelica gigas, Aconitum carmichaelii, and Zingiber officinale Roscoe, is rich in bioactive compounds with anti-inflammatory and antioxidant activities. While JI017 has shown anticancer effects in various malignancies, its mechanisms in HCC have not been well characterized.
methodsThe impact of JI017 on HCC cells was evaluated using cell viability, colony formation, wound healing, apoptosis, and cell cycle assays. Apoptosis, cell cycle changes, and STAT3 pathway modulation were measured via Western blotting and RT-qPCR.
resultsJI017 reduced cell proliferation and migration in both HCC cell lines in a dose-dependent manner. In SNU-387 cells, JI017 strongly induced apoptosis, demonstrated by increased CHOP and DR4 expression and altered apoptosis-related proteins, indicating involvement of both intrinsic and extrinsic pathways. In HepG2 cells, JI017 mainly induced G0/G1 phase arrest, characterized by decreased levels of Cyclin/CDK complexes and increased p21 and p27 expression. Mechanistically, JI017 suppressed STAT3 activation by decreasing Tyr705 phosphorylation, reducing total STAT3 levels, and lowering upstream activators p-JAK2 and p-SRC. This resulted in downregulation of STAT3-regulated genes Cyclin D1, Survivin, and Bcl-2. These anticancer effects were similar or greater than those observed with Stattic, a recognized STAT3 inhibitor.
conclusionJI017 exerts cell line-specific anticancer effects in HCC through STAT3 pathway suppression, resulting in apoptosis in SNU-387 and cell cycle arrest in HepG2. These results support the potential of JI017 as a STAT3-targeted therapeutic candidate for HCC.
Indexed as
Identifiers
41460538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.